RSS

cardiovascular

A weight loss drug, lorcaserin — currently available in the US, has been found to offer sustained weight loss in patients without a higher rate of cardiovascular events when compared with placebo in a recently published study. Read more

News

Monoclonal antibodies (MAb) solutions are a major class of biopharmaceuticals with various applications. They are important for treating diseases such as cancer, inflammation, allergies, infectious diseases and cardiovascular diseases. Read more

Primary data from the CANTOS Phase III trial (sponsored by Novartis) has revealed that a treatment that targets inflammation reduces the risk of cardiovascular disease. Read more

News

A study from researchers at Yale School of Medicine, evaluating cardiovascular trials with primary surrogate endpoints from the past 20 years, have found a disconnect between these trials and clinical outcomes. Read more

News

A recent study, published in the Lancet, suggests that common side effects of statins, namely muscle pain and weakness, are not directly a result of the drugs but more because of patients’ negative expectations. Read more

News

Nemera is contributing to the EU-funded project Cardio Ultraefficient nanoParticles for Inhalation of Drug prOducts (Cupido), which is aimed at applying nanotechnologies to the cardiovascular field. Read more

News

The FDA has issued a complete response letter denying Merck’s application to include cardiovascular information on its drug labels for its diabetes drugs, Januvia and Janumet. Read more

News

A recent study has linked the use of ibuprofen with increased cardiovascular risk. Read more

News

A new pill made entirely out of chocolate has been shown to help cut the risk of heart attacks, strokes and dementia. Read more

News

Laboratoris Sanifit has appointed Dr Preston S. Klassen, MD, MHS as its chief medical officer and announced the launch of its US Subsidiary, based in San Diego, USA. Read more

News

Martindale Pharma’s Noyada, a medication that targets heart conditions in children, has been approved for early access in France due to an ATU de’ Cohorte (Temporary Authositaion for Use) programme Read more

News

Sanofi and Regeneron Pharmaceuticals have completed enrollment in the global phase three, Odyssey Outcomes trial for patients suffering from acute coronary syndrome (ACS) Read more

News

Novartis Access has launched in in Kenya. It will be the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer Read more

News

Regulatory affairs services provider ELC Group is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas. Read more

News